

**Study Name:** A Genotype-Phenotype Urothelial Cancer Study **Institution:** Memorial Sloan-Kettering Cancer Center

**Principal Investigators:** Drs. Dean Bajorin/Kenneth Offit **Institution address:**  
Memorial Sloan-Kettering Cancer Center  
1275 York Ave  
New York, NY, 10065  
Phone: 646 888 4067

**Key References:** None as yet **Additional researchers:** Drs. Mia Gaudet, David Gallagher, Robert Hamilton

**Study Design:** Hospital Based  
Case-control

**Matching factors:** Age, sex, race

**Country:** USA

**ICD-0-3 morphology codes:** all  
below codes

**Follow up of cases?** Yes

**Expected time of follow-up?**  
1yr questionnaire; on-going clinical

**Urinary Bladder ICD-0-3 morphology codes:** Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903);

	Cases	Controls
<b>Years of enrollment</b>	May 2009-present	May 2009-present
<b>Source population</b>	MSKCC oncology and urology outpatient clinics	Genetically unrelated people accompanying cases to clinic; patients presenting to MSKCC clinics without any cancer history
<b>Response rate (enrolled/eligible)</b>	NA	NA
<b>Total number enrolled</b>	840	344
<b>Subjects with DNA</b>	840	344
<b>Ethnic origin</b>	Mixed	Mixed
<b>Age: mean (range)</b>	68 (22-96)	62 (23-88)
<b>Gender: % males</b>	76%	31%

Questionnaire data	Cases	Controls
<b>Demographics (age, sex, ethnicity, region, education etc..)</b>	X	X
<b>Active smoking</b>	X	X
<b>Passive smoking</b>	X	X
<b>Occupational exposures</b>	X	X
<b>Residential history</b>		
<b>Water chlorination byproducts</b>		
<b>Arsenic exposure</b>		
<b>Other environmental exposures</b>		
<b>Hair dye use</b>	X	X
<b>Drug use</b>	X	X
<b>Medical History</b>	X	X-partial
<b>Family History</b>	X	
<b>Quality of life</b>		
<b>Diet/nutrition</b>		
<b>Caffeine intake</b>	X	X
<b>Fluid intake</b>	X	X
<b>Urine pH measurements</b>		
<b>Other information, please specify</b>		

**Biological Samples**

**Cases**

**Controls**

Blood DNA		
Buccal DNA	X	X
Serum/plasma		
Cryopreserved whole blood / lymphocytes		
Red blood cells		
Urine samples		
Toenail clippings		
Others, please specify		
Paraffin tissue blocks	X	
Frozen tissue	X (some)	

**For Cases Only**

**Note : Approximately half of our patients are classified as superficial disease, and some more data is collected on them (indicated by "S" below)**

**Information at time of diagnosis**

Histological confirmation	X
Number of tumors	
Tumor site	X
Tumor size	
Tumor grade	X
Growth pattern	
Treatment of primary tumor	X
Stage	X
Other information, please specify	

**Follow-up information**

Treatment information	X
Tumor recurrence	X
Tumor progression	S
Survival	X
Histological confirmation	S
Number of tumors	X
Tumor site	X
Tumor size	S
Tumor grade	S
Growth pattern	S
Stage	S
Active smoking	X
Occupational exposures	
Drug use	
Medical History	X
Quality of life	
Caffeine intake	
Fluid intake	
Other information , please specify	

<b>Study Name (Symbol):</b> Spanish Bladder Cancer Study (SBCS)	<b>Institution/s:</b> National Cancer Institute Division of Cancer Epidemiology and Genetics (NCI-DCEG), Rockville, MD  Institut Municipal d'Investigacio Medica ( <b>IMIM</b> ), Barcelona, Spain
<b>Principal Investigators:</b> <b>NCI-DCEG:</b> Debra Silverman, Nathaniel Rothman, Montse Garcia-Closas  <b>IMIM:</b> Manolis Kogevinas, Nuria Malats, Paco Real	<b>Institution/s address:</b> <b>NCI-DCEG</b> 6120 Executive Boulevard Bethesda, MD USA 20852-7234 <b>IMIM</b> Centre for Research in Environmental Epidemiology (CREAL), Respiratory and Environmental Health Research Unit, Dr Aiguader 80, 08003 Barcelona, Spain
<b>Key References:</b> Rothman N et al. <i>Nature Gen.</i> 2010 Nov;42(11):978-84 Cantor K et al. <i>Environ Health Perspect.</i> 2010 Jul 30. [Epub] Silverman DT. <i>Int J Cancer.</i> 2008 Oct 1;123(7):1644-8. Samanic C et al. <i>Cancer Epidemiol Biomarkers Prev.</i> 2006 Jul;15(7):1348-54 Lopez-Knowles E et al. <i>Clin Cancer Res.</i> 2006 Oct 15;12(20 Pt 1):6029-36 Garcia-Closas M et al. <i>Lancet.</i> 2005 Aug 20-26;366(9486):649-59	<b>Additional researchers:</b> Kenneth Cantor, NCI-DCEG Joan Fortuny, IMIM Montserrat Garcia-Closas, NCI-DCEG Lee Moore, NCI-DCEG Jonine Figueroa, NCI-DCEG Joanne Colt, NCI-DCEG Ludmila Prokunina, NCI-DCEG Claudine Samanic, NCI-DCEG Stephen Chanock, NCI-DCEG
<b>IRB Information</b> <b>Name of PI for the IRB approved protocol</b> Debra Silverman	

<b>Study Design:</b> Hospital based Case-Control	<b>Matching factors:</b> Gender, age, hospital/region	<b>Country:</b> Spain
<b>ICD-0-3 morphology codes:</b> 81203, 80703, 81303, 81403	<b>Follow up of cases?</b> Yes	<b>Expected time of follow-up?</b> 64 - 90 months

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1998-2001	1998-2001
<b>Source population</b>	18 hospitals in 5 regions of Spain	18 hospitals in 5 regions of Spain
<b>Response rate (enrolled/eligible)</b>	84%	88%
<b>Total number enrolled</b>	1219	1271
<b>Subjects with DNA</b>	1150	1149
<b>Ethnic origin</b>	99% Caucasian	99% Caucasian
<b>Age: mean (range)</b>	66 (21-80)	65(21-80)
<b>Gender: % males</b>	87%	87%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts	x	x
Arsenic exposure		
Other environmental exposures	x	x
Hair dye use	x	x
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life	x	x
Diet/nutrition	x	x

Caffeine intake	X	X
Fluid intake	X	X
Urine pH measurements	X	X
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	X	X
Buccal DNA	X	X
Serum/plasma	X	X
Cryopreserved whole blood / lymphocytes	X	X
Red blood cells	X	X
Urine samples	-	-
Toenail clippings	X	X
Others, please specify	-	-
Paraffin tissue blocks	X	
Frozen tissue	-	

### For Cases Only

Information at time of diagnosis	
Histological confirmation	X
Number of tumors	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	X
Treatment of primary tumor	-
Stage	X
Other information, please specify	-
Follow-up information	
Treatment information	X
Tumor recurrence	X
Tumor progression	-
Survival	X
Histological confirmation	X
Number of tumors	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	X
Stage	X
Active smoking	X
Occupational exposures	X
Drug use	X
Medical History	X
Quality of life	X
Caffeine intake	X
Fluid intake	X
Other information , please specify	-

**Study Name :**  
New England Bladder Cancer Study

**Institutions:**  
National Cancer Institute Division of Cancer  
Epidemiology and Genetics (NCI-DCEG)  
Dartmouth Medical School  
New Hampshire Department of Health and Human  
Services  
Maine Department of Health and Human Services,  
Vermont Cancer Registry

**Principal Investigators:**

**NCI-DCEG:** Debra Silverman, Dalsu Baris

**Dartmouth Medical School:** Margaret Karagas, Richard  
Wadell

**Department of Health and Human Services, Maine  
Cancer Registry:** Molly Schwenn

**VT Cancer Registry:** Alison Johnson

**Key References:**

Baris D. et al. J Natl Cancer Inst. 2009 Nov 18;  
101(22):1553-61. Epub 2009 Nov 16.  
Colt JS, et al. Occup Environ Med. 2010 Sep 23.  
[Epub ahead of print]  
Moore L, et al. Carcinogenesis. 2010 Oct 29.  
[Epub ahead of print]

**Institution address:**

**NCI-DCEG:**  
6120 Executive Boulevard  
Bethesda, MD USA 20852-7234

**Dartmouth Medical School:**  
7927 Rubin Building, One Medical Center Drive,  
Lebanon, NH 03756

**Department of Health and Human Services, Maine  
Cancer Registry:**

Key Bank Plaza, 4th Floor  
Augusta, ME 04333

**VT Cancer Registry:**  
108 Cherry Street, Burlington, VT 05401

**Additional researchers:**

Angeline Andrew (Dartmouth Medical School)  
Bill Apao (Vermont)  
Laura Beane-Freeman (NCI)  
Ken Cantor (NCI, Lead Investigator)  
Sai Cherala (New Hampshire)  
Montserrat Garcia-Closas (NCI)  
Joanne Colt (NCI, Lead Investigator)  
Jay Lubin (NCI)  
Lee Moore (NCI)  
Nathaniel Rothman (NCI, Lead Investigator)  
Alan Schned (Dartmouth Medical School)  
Castine Verrill (Maine)

**Study Design:** Population based Case-Control  
**ICD-9 code:** 189.8  
**ICD-0-3 morphology codes:** 7400/6, 7400/7,  
8010/2, 8032/3, 8041/3, 8053/0, 8070/3, 8120/3,  
8130/3, 8140/3

**Matching factors:** age and sex  
**Follow up of cases?** Feasibility  
study is being initiated

**Country:** USA  
**Expected time of follow-  
up?**

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303);  
Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	2001-2004	2001-2004
<b>Source population</b>	Newly diagnosed incident cases in the states of New Hampshire, Maine and Vermont	Frequency matched controls selected from Department of Motor Vehicle (<65 years of age) and Centers of Medicare and Medicaid Services (>=65 years of age)
<b>Response rate (enrolled/eligible)</b>	65%	65%
<b>Total number enrolled</b>	1,213	1,418
<b>Subjects with DNA</b>	1,134	1,306
<b>Ethnic origin</b>	94% Caucasian	94% Caucasian
<b>Age: mean (range)</b>	65.16 (30-79)	64.52 (30-79)
<b>Gender: % males</b>	76% males	73%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x

Active smoking	X	X
Passive smoking	X	X
Occupational exposures	X	X
Residential history	X	X
Water chlorination byproducts	X	X
Arsenic exposure	X	X
Other environmental exposures	X	X
Hair dye use	X	X
Drug use	X	X
Medical History	X	X
Family History	X	X
Quality of life	-	-
Diet/nutrition	X	X
Caffeine intake	X	X
Fluid intake	X	X
Urine pH measurements	X	X
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	X	X
Buccal DNA	X	X
Serum/plasma	X	X
Cryopreserved whole blood / lymphocytes	X	X
Red blood cells	X	X
Urine samples	X	X
Toenail clippings	X	X
Others, please specify	-	-
Paraffin tissue blocks	X	
Frozen tissue	-	

#### For Cases Only

Information at time of diagnosis	
Histological confirmation	X
Number of tumors	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	X
Treatment of primary tumor	-
Stage	X
Other information, please specify	-

Follow-up information	
Treatment information	-
Tumor recurrence	-
Tumor progression	-
Survival	-
Histological confirmation	-
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	-
Growth pattern	-
Stage	-
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-

**Study Name:**

Nijmegen Bladder Cancer Study

**Institution:**

Radboud University Nijmegen Medical Centre (RUNMC)  
 Nijmegen, the Netherlands  
 Comprehensive Cancer Centre East (IKO)  
 Nijmegen, the Netherlands

**Principal Investigators:**

Prof. Dr. Lambertus (Bart) A. Kiemeny (RUNMC)  
 Dr. Katja K.H. Aben (IKO)  
 Dr. Sita H. Vermeulen (RUNMC)

**Institution address:**

Radboud University Nijmegen Medical Centre (RUNMC)  
 Department of Epidemiology and Biostatistics (133)  
 Department of Urology (459)  
 P.O. Box 9101  
 NL-6500 HB Nijmegen, the Netherlands

**Key References:**

Kiemeny LA, Sulem P, Besenbacher S, et.al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42(5): 415-9.  
 Kiemeny LA, Thorlacius S, Sulem P, et.al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008; 40(11): 1307-1312.

Comprehensive Cancer Centre East (IKO)  
 P.O. Box 1281  
 NL-6501 BG Nijmegen, the Netherlands

**Additional researchers:**

Prof. Dr. J. Alfred (Fred) Witjes, RUNMC  
 Dr. Martin den Heijer, RUNMC  
 Dr. Dorine Swinkels, RUNMC  
 Dr. Barbara Franke, RUNMC

**Study Design:**

Population-based case-control. Cases have been retrospectively and are prospectively being identified and recruited from the population-based cancer registry of IKO

**Matching factors:****Country:**

the Netherlands

**ICD-0-3 morphology codes:**

8000, 8020, 8041, 8045, 8070, 8071, 8120, 8130, 8140, 8246, 8480, 8481, 8490, 8560, 8700

**Follow up of cases? Yes****Expected time of follow-up?**

Currently 1-15 years

	Cases	Controls
<b>Years of enrollment</b>	2007-2010 (years of diagnosis 1975-2009)	2002-2003
<b>Source population</b>	IKO Population-based cancer registry, covering 8 hospitals and 1.3 million inhabitants	Nijmegen Municipal Population Administration covering 150,000 inhabitants
<b>Response rate (enrolled/eligible)</b>	62%	9,350 / 21,756 -> 43%
<b>Total number enrolled</b>	1974	9,350
<b>Subjects with DNA</b>	1914	6468
<b>Ethnic origin</b>	>99% Caucasian	>99% Caucasian
<b>Age: mean (range)</b>	62.3 range (25-93)	54 (18 – 100)
<b>Gender: % males</b>	81.5%	46

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking		
Occupational exposures	x	x
Residential history		
Water chlorination byproducts		
Arsenic exposure		
Other environmental exposures		
Hair dye use	x	x
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life		
Diet/nutrition	x	x

Caffeine intake		x
Fluid intake	x	
Urine pH measurements		
Other information, please specify:	physical activity, artificial sweeteners, urination frequency	physical activity
* incl. urinary tract infections treated with antibiotics, bladder stones, catheter, X-ray exposure abdomen/pelvis		
# exposure during conception / pregnancy first child, including cosmetic products, X-ray, anaesthetics, cytostatics, industrial cleaners, paint, pesticides.		

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	-	x
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	x
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	x	
Frozen tissue	-	

### For Cases Only

Information at time of diagnosis	
Histological confirmation	x
Number of tumors	
Tumor site	x
Tumor size	
Tumor grade	x
Growth pattern	
Treatment of primary tumor	x
Stage	x
Other information, please specify	
Follow-up information	
Treatment information	
Tumor recurrence	x
Tumor progression	x
Survival	x
Histological confirmation	x
Number of tumors	x
Tumor site	x
Tumor size	x
Tumor grade	x
Growth pattern	x
Stage	x
Active smoking	x
Occupational exposures	
Drug use	
Medical History	x
Quality of life	
Caffeine intake	
Fluid intake	
Other information , please specify	



**Study Name:**  
M.D. Anderson Bladder Cancer Study

**Institution:**  
The University of Texas M. D. Anderson Cancer Center

**Principal Investigators:**  
Xifeng Wu

**Institution address:**  
1515 Holcombe Blvd, Houston, TX 77030

**Key References:**  
**PMID**

Wu X. et al. 2009 Nat Genet 41 (9) 991-5.  
Wu X. et al. 2007. J Clin Oncol 25 (31): 4974-81.

**Additional researchers:**

**Study Design:**  
Hospital based Case-Control  
**ICD-0-3 morphology codes:**  
189.8

**Matching factors:**  
Age, gender, ethnicity  
**Follow up of cases? Yes**

**Country:**  
USA  
**Expected time of follow-up?**

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1999-2009	1999-2009
<b>Source population</b>	M.D. Anderson Hospital	Houston Metropolitan Area
<b>Response rate (enrolled/eligible)</b>	92%	77%
<b>Total number enrolled</b>	1542	1610
<b>Subjects with DNA</b>	1542	1610
<b>Ethnic origin</b>	Caucasian 91.8% Hispanic 3.8% African American 3.5% Other 0.9%	Matched to cases
<b>Age: mean (range)</b>	63.4 (18-89)	62.5 (21-89)
<b>Gender: % males</b>	79.1%	77.4%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	x	x
Hair dye use	x	x
Drug use	-	-
Medical History	x	x
Family History	x	x
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	-	-
Fluid intake	x	x
Urine pH measurements	-	-
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	x	x
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	-
Toenail clippings	-	-
Others, please specify	-	-

Paraffin tissue blocks	-
Frozen tissue	-

### For Cases Only

#### Information at time of diagnosis

Histological confirmation	X
Number of tumors	-
Tumor site	-
Tumor size	X
Tumor grade	X
Growth pattern	-
Treatment of primary tumor	X
Stage	X
Other information, please specify	-

#### Follow-up information

Treatment information	X
Tumor recurrence	X
Tumor progression	X
Survival	X
Histological confirmation	X
Number of tumors	X
Tumor site	-
Tumor size	X
Tumor grade	X
Growth pattern	-
Stage	X
Active smoking	X
Occupational exposures	X
Drug use	-
Medical History	X
Quality of life	-
Caffeine intake	-
Fluid intake	X
Other information , please specify	-

**Study Name:**  
The Los Angeles-Shanghai Bladder Cancer Study

**Institution:**  
USC/Norris Comprehensive Cancer Center  
University of Minnesota Cancer Center

**Principal Investigators:**  
Ronald K. Ross (deceased, now Malcolm C. Pike)  
USC

**Institution address:**  
USC/Norris Cancer Center  
1441 Eastlake Avenue  
Los Angeles, California 90089

Jian-Min Yuan, subcontract to University of  
Minnesota

University of Minnesota Cancer Center  
1300 South Second Street, Suite 300  
Minneapolis, Minnesota 55454

**Key References:**  
(1) Int J Cancer 2004 110: 417; (2) Carcinogenesis 2003  
24: 1645; (3) Eur J Epidemiol 2003 18: 659; (4) CEBP  
2003 12: 503; (5) Carcinogenesis, 24: 483-489, 2003; (6) J  
Natl Cancer Inst 2001 93: 538; (7) Int J Cancer 2001 91  
575; (8) Br J Cancer 2000 82: 1364.

**Additional researchers:**  
University of Minnesota: Mimi C. Yu  
USC: J. Esteban Castelao, David Conti,  
Victoria Cortessis, Manuela Gago-Dominguez,  
Mariana Stern, Duncan Thomas,  
David Van Den Berg

**Study Design:** Population based Case-  
Control

**Matching factors:** Age, gender, sex

**Country:** United States and China

**ICD-0-3 morphology codes:** -

**Follow up of cases?-**

**Expected time of follow-up?-**

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303);  
Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	<b>LA:</b> 1988-1999 <b>Shanghai:</b> 1996-1999	<b>LA:</b> 1988-1999 <b>Shanghai:</b> 1996-1999
<b>Source population</b>	<b>LA:</b> non-Asian residents of Los Angeles County, California <b>Shanghai:</b> Han Chinese residents of city of Shanghai	<b>LA:</b> non-Asian residents of Los Angeles County, California <b>Shanghai:</b> Han Chinese residents of city of Shanghai
<b>Response rate (enrolled/eligible)</b>	<b>LA:</b> 70% (1671/2384) <b>Shanghai:</b> 83% (622/749)	<b>LA:</b> 69% 1 <sup>st</sup> and 31% ≥2 <sup>nd</sup> eligible controls <b>Shanghai:</b> 84%
<b>Total number enrolled</b>	<b>LA:</b> 1671 <b>Shanghai:</b> 622	<b>LA:</b> 1568 <b>Shanghai:</b> 610
<b>Subjects with DNA</b>	<b>LA:</b> 723 <b>Shanghai:</b> 545	<b>LA:</b> 760 <b>Shanghai:</b> 537
<b>Ethnic origin</b>	<b>LA:</b> 92.3% non- Hispanic white 4.3% Hispanic white 3.3% African American 0.1% Native American <b>Shanghai:</b> Han Chinese	
<b>Age: mean (range)</b>	<b>LA:</b> 56 (25-69) <b>Shanghai:</b>	<b>LA:</b> 56 (25-69) <b>Shanghai:</b>
<b>Gender: % males</b>	<b>LA:</b> 78.6% <b>Shanghai:</b> 79%	<b>LA:</b> 78.0% <b>Shanghai:</b> 77%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	X	X
Active smoking	X	X
Passive smoking among lifelong nonsmokers	X	X
Occupational exposures	X	X
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	X	X
Hair dye use	X	X
Drug use	X	X
Medical History	X	X
Family History	X	X
Quality of life	-	-
Diet/nutrition	X	X
Caffeine intake (incomplete coverage?)	X	X
Fluid intake (incomplete coverage?)	X	X
Urine pH measurements	X	X
Other information, use of hormone for women only	X	X

Biological Samples	Cases	Controls
Blood DNA	X	X
Buccal DNA	-	-
Serum/plasma	X	X
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	X	X
Urine samples	X	X
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	X	
Frozen tissue	-	

#### For Cases Only

Information at time of diagnosis	
Histological confirmation	-
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	-
Growth pattern	-
Treatment of primary tumor	-
Stage	-
Other information, please specify	-
Follow-up information	
Treatment information	-
Tumor recurrence	-
Tumor progression	-
Survival	-
Histological confirmation	-
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	-
Growth pattern	-
Stage	-
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-

**Study Name:**  
New Hampshire Bladder Cancer Study

**Institution:**  
Dartmouth Medical School Section of biostatistics and epidemiology

**Principal Investigators:**  
Margaret R Karagas

**Institution address:**  
7927 Rubin Building  
One Medical Center Drive  
Lebanon, NH 03756"

**Key References:**  
Karagas MR. et al. Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50.; Danaee H. et al. Oncogene. 2002 Jul 25;21(32):4894-9.; Andrew AS. et al. Int J Cancer. 2004 Apr 20;109(4):581-6.

**Additional researchers:**  
Alan Schned  
Karl Kelsey  
Angeline Andrew  
Carmin Marsit

**Study Design:**  
Population-based Case-Control  
**ICD-0-3 morphology codes:**  
**All**

**Matching factors:**  
None  
**Follow up of cases?**  
**Yes**

**Country:**  
USA  
**Expected time of follow-up?**  
5-15 years or longer

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1994-2001	1994-2001
<b>Source population</b>	New Hampshire USA	New Hampshire USA
<b>Response rate (enrolled/eligible)</b>	85%	70%
<b>Total number enrolled</b>	847	1091
<b>Subjects with DNA</b>	728	995
<b>Ethnic origin</b>	>90% White, Non-Hispanic	
<b>Age: mean (range)</b>	62	61
<b>Gender: % males</b>	84%	76%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts	x	x
Arsenic exposure	x	x
Other environmental exposures	x	x
Hair dye use	x	x
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements	-	-
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	x	x
Serum/plasma	x	x
Cryopreserved whole blood / lymphocytes	x	x
Red blood cells	x	x
Urine samples	-	x
Toenail clippings	x	x

Others, please specify	-	-
Paraffin tissue blocks	X	
Frozen tissue	-	

**For Cases Only**

<b>Information at time of diagnosis</b>		
Histological confirmation	X	
Number of tumors	X	
Tumor site	X	
Tumor size	X	
Tumor grade	X	
Growth pattern	X	
Treatment of primary tumor	X	
Stage	X	
Other information, please specify % of tumor	X	
<b>Follow-up information</b>		
Treatment information	X	
Tumor recurrence	X	
Tumor progression	X	
Survival	X	
Histological confirmation	X	
Number of tumors	X	
Tumor site	X	
Tumor size	X	
Tumor grade	X	
Growth pattern	-	
Stage	X	
Active smoking	X	
Occupational exposures	-	
Drug use	X	
Medical History	X	
Quality of life	-	
Caffeine intake	-	
Fluid intake	-	
Other information , please specify, passive smoking	X	

**Study Name:**  
Leeds Bladder Cancer Study (Molecular Epidemiology of DNA repair and Bladder Cancer)

**Institution:** Gray Institute for Radiation Oncology and Biology

**Principal Investigators:**  
Dr. Anne E. Kiltie

**Institution address:** Old Road Campus Research Building  
Off Roosevelt Drive, OXFORD OX3 7DQ

**Key References:**  
Sak SC, Barrett J, Paul A, Bishop DT, Kiltie AE (2005)  
*British Journal of Cancer* 92:2262-2265.  
Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE (2006)  
*Cancer Epidemiology Biomarkers and Prevention*  
15:2537-41.

**Additional researchers:**  
D Tim Bishop, CR-UK  
Jennifer H Barrett, CR-UK  
Sei Chung Sak, now NHS  
Alan B Paul, NHS

<b>Study Design:</b> Hospital-based case control	<b>Matching factors:</b> Age and gender	<b>Country:</b> UK
<b>ICD-0-3 morphology codes:</b> 81203	<b>Follow up of cases? Yes</b>	<b>Expected time of follow-up?</b> Currently 3-5 years

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	2002-ongoing	2002-2004
<b>Source population</b>	County of West Yorkshire UK	County of West Yorkshire UK
<b>Response rate (enrolled/eligible)</b>	900/1100	Approx 80%
<b>Total number enrolled</b>	1100	900
<b>Subjects with DNA</b>	1100	900
<b>Ethnic origin</b>	98.5% Caucasian	98.5% Caucasian
<b>Age: mean (range)</b>	72.8 years	71.9 years
<b>Gender: % males</b>	71%	65%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	-	-
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	-	-
Hair dye use	-	-
Drug use	-	-
Medical History	-	-
Family History	x	x
Quality of life	-	-
Diet/nutrition	-	-
Caffeine intake	-	-
Fluid intake	-	-
Urine pH measurements	-	-
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	-	-
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	-
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	x	-
Frozen tissue	-	-

## For Cases Only

Information at time of diagnosis	
Histological confirmation	X
Number of tumors	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	X
Treatment of primary tumor	X
Stage	X
Other information, please specify	-
Follow-up information	
Treatment information	X
Tumor recurrence	X
Tumor progression	X
Survival	X
Histological confirmation	X
Number of tumors	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	X
Stage	X
Active smoking	X
Occupational exposures	X
Drug use	X
Medical History	X
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-



**Study Name:**  
Torino bladder cancer

**Institution:**  
Dipartimento di Scienze Biomediche e Oncologia  
Umana

**Principal Investigators:**  
Giuseppe Matullo  
Paolo Vineis

**Institution address:**  
Via Santena 7 10126 Torino Italy

**Key References:**

**Additional researchers:**  
Carlotta Sacerdote

**Study Design:**  
Hospital-based Case-Control  
**ICD-0-3 morphology codes:**  
**81203, 81303, 80703, 81403, 81402**

**Matching factors:**  
**Follow up of cases? Yes**

**Country:**  
Italy  
**Expected time of follow-up? 15/07/2007**

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1994-2007	1994-2007
<b>Source population</b>	Torino metropolitan area	Torino metropolitan area
<b>Response rate (enrolled/eligible)</b>		
<b>Total number enrolled</b>	439	512
<b>Subjects with DNA</b>	422	414
<b>Ethnic origin</b>	100% Italian Caucasian	
<b>Age: mean (range)</b>	57.3 (42-74)	57.3 (40-74)
<b>Gender: % males</b>	100%	100%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	-	-
Hair dye use	-	-
Drug use	x	x
Medical History	-	-
Family History	x	x
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements	-	-
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	x	x
Cryopreserved whole blood / lymphocytes	x	-
Red blood cells	-	-
Urine samples	x	x
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	-	-
Frozen tissue	-	-

**For Cases Only**

Information at time of diagnosis	
Histological confirmation	X
Number of tumors	-
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	-
Treatment of primary tumor	X
Stage	-
Other information, please specify Morphology	X
Follow-up information	
Treatment information	-
Tumor recurrence	-
Tumor progression	-
Survival	X
Histological confirmation	-
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	-
Growth pattern	-
Stage	-
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify: Cause of death	X

<b>Study Name:</b> Molecular Epidemiology of Bladder Cancer and Prostate Cancer	<b>Institution:</b> University of California in Los Angeles (UCLA)
<b>Principal Investigators:</b> Zuo-Feng Zhang	<b>Institution address:</b> UCLA Center for Environmental Genomics UCLA School of Public Health 71-225 CHS, Box 951772 650 Charles Young Drive, South Los Angeles, CA 90095-1772 310-825-8418 (Office)

<b>Key References:</b> Cao W, et al. Cancer. 2005 Dec 1;104(11):2400-8. Hung RJ, J Urol . 2006 Sep;176(3):1192-7. Yang YC, et al.Br J Cancer. 2006 Dec 4;95(11):1455-8.	<b>Additional researchers:</b>
--	--------------------------------

<b>Study Design:</b> Hospital-based Case-control	<b>Matching factors:</b> Un-matched	<b>Country:</b> U.S.A.
<b>ICD-0-3 morphology codes:</b> 81203, 81303, 80703, 81403	<b>Follow up of cases?</b> Yes	<b>Expected time of follow-up?</b> 60-120 months

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1993-1997	1993-1997
<b>Source population</b>	MSKCC, hospital	MSKCC, hospital
<b>Response rate (enrolled/eligible)</b>	94.6%	91.9%
<b>Total number enrolled</b>	229	204
<b>Subjects with DNA</b>	170	158
<b>Ethnic origin</b>	97.1% Caucasian	97.5% Caucasian
<b>Age: mean (range)</b>	64.9	42.2
<b>Gender: % males</b>	82.9%	76.6%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking (only for non smokers-ex smokers)	x	x
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts		
Arsenic exposure	x	x
Other environmental exposures	x	x
Hair dye use (available after follow up)	x	x
Drug use (available after follow up)		
Medical History (available after follow up)	x	x
Family History	x	x
Quality of life		
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements		
Other information, please specify (alcohol, tea, soft drinks; diuresis)	Alcohol, physical activities, pain relievers, etc	Alcohol, physical activities, pain relievers, etc

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA		
Serum/plasma	x	x
Cryopreserved whole blood / lymphocytes		
Red blood cells	x	x

Urine samples	
Toenail clippings	
Others, please specify	
Paraffin tissue blocks	
Frozen tissue	X

**For Cases Only**

**Information at time of diagnosis**

Histological confirmation	X
Number of tumors (available after follow up)	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	
Treatment of primary tumor	
Stage	
Other information, please specify	

**Follow-up information**

Treatment information	
Tumor recurrence	
Tumor progression	
Survival	X
Histological confirmation	
Number of tumors	
Tumor site	
Tumor size	
Tumor grade	
Growth pattern	
Stage	
Active smoking	
Occupational exposures	
Drug use	
Medical History	
Quality of life	
Caffeine intake	
Fluid intake	
Other information , please specify (as above)	

<b>Study Name:</b> Lutherstadt Wittenberg Bladder Cancer Study (LWBCS)	<b>Institution:</b> Leibniz Research Centre for Working Environment and Human Factors (IfADo)
<b>Principal Investigators:</b> IfADo: Klaus Golka, Jan G. Hengstler	<b>Institution address:</b> IfADo Ardeystr. 67 44139 Dortmund Germany Tel: +49 231 1084 344 Fax: +49 231 1084 308
<b>Key References:</b>  Golka K. et al: <i>J. Toxicol. Environ. Health Part A</i> 2008 71:881-6  Zimmermann A. et al: <i>J. Toxicol. Environ. Health Part A</i> 2008 71:911-4	<b>Additional researchers:</b> Silvia Selinski, IfADo Meinolf Blaszkewicz, IfADo Matthias Hermes, IfADo

<b>Study Design:</b> Hospital based Case-Control	<b>Matching factors:</b> Gender, age, hospital	<b>Country:</b> Germany
<b>ICD-0-3 morphology codes:</b> Transitional cell carcinoma (according to ICD 10)	<b>Follow up of cases? Yes</b>	<b>Expected time of follow-up?</b> At least 114 months

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	Dec 1995-Jan 1999	Jul 2000-Apr 2005
<b>Source population</b>	1 hospital	1 hospital
<b>Response rate (enrolled/eligible)</b>		
<b>Total number enrolled</b>		
<b>Subjects with DNA</b>	216	211
<b>Ethnic origin</b>	German	German
<b>Age: mean (range)</b>	67 (20-93)	67 (29-91)
<b>Gender: % males</b>	186	175

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, etc..)	X	X
Active smoking	X	X
Passive smoking (only for non smokers-ex smokers)	-	-
Occupational exposures	X	X
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	-	-
Hair dye use	-	-
Drug use (available for pain killers only)	X	X
Medical History	-	-
Family History (related to bladder cancer)	X	X
Quality of life	-	-
Diet/nutrition	-	-
Caffeine intake	-	-
Fluid intake	-	-
Urine pH measurements	-	-
Other information, please specify (alcohol, tea, soft drinks; diuresis)		

Biological Samples	Cases	Controls
Blood DNA	X	X
Buccal DNA	-	-
Serum/plasma	-	-

Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	-
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	Asked	
Frozen tissue	-	

### For Cases Only

#### Information at time of diagnosis

Histological confirmation	X
Number of tumors (available after follow up)	-
Tumor site	-
Tumor size	-
Tumor grade	X
Growth pattern	-
Treatment of primary tumor	X
Stage	X
Other information, please specify	

#### Follow-up information

Treatment information	X
Tumor recurrence (available after follow up)	X
Tumor progression (available after follow up)	X
Survival (available after follow up)	X
Histological confirmation	X
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	X
Growth pattern	-
Stage	X
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information, please specify (as above)	-

**Study Name:**  
Eastern European Bladder Cancer Study

**Principal Investigators:**  
Tony Fletcher

**Key References:**

**Institution:**  
PEHRU Public and Environmental Health Research Unit  
London School of Hygiene & Tropical Medicine  
**Institution address:**  
PEHRU Public and Environmental Health Research Unit,  
London School of Hygiene & Tropical Medicine, Keppel  
Street, London WC1E 7HT, UK  
**Additional researchers:**

**Study Design:**  
Hospital-based case control  
**ICD-0-3 morphology codes:**

**Matching factors:**  
Age, gender  
**Follow up of cases?**  
No

**Country:**  
Hungary, Romania, Slovakia  
**Expected time of follow-up?**  
NA

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	2002-2004	2002-2004
<b>Source population</b>	Hungary, Romania and Slovakia	Hungary, Romania and Slovakia
<b>Response rate (enrolled/eligible)</b>	85.3%	
<b>Total number enrolled</b>	214	540
<b>Subjects with DNA</b>	214	540
<b>Ethnic origin</b>	Caucasian	Caucasian
<b>Age: mean (range)</b>	30-79	30-79
<b>Gender: % males</b>		

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts		
Arsenic exposure	x	x
Other environmental exposures		
Hair dye use		
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life		
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements		
Other information, please specify	x	x

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	x	x
Serum/plasma		
Cryopreserved whole blood / lymphocytes		
Red blood cells		
Urine samples		
Toenail clippings		
Others, please specify		
Paraffin tissue blocks		
Frozen tissue		

## For Cases Only

### Information at time of diagnosis

Histological confirmation	x
Number of tumors	
Tumor site	
Tumor size	
Tumor grade	x
Growth pattern	
Treatment of primary tumor	
Stage	
Other information, please specify	

### Follow-up information

Treatment information	
Tumor recurrence	
Tumor progression	
Survival	
Histological confirmation	
Number of tumors	
Tumor site	
Tumor size	
Tumor grade	
Growth pattern	
Stage	
Active smoking	
Occupational exposures	
Drug use	
Medical History	
Quality of life	
Caffeine intake	
Fluid intake	
Other information , please specify	



**Study Name:**  
Brescia bladder cancer case-control study

**Institution:**  
Institute of Occupational Health, University of Brescia,  
Italy

**Principal Investigators:**  
Stefano Porru

**Institution address:**  
P.le Spedali Civili, 1  
25125 Brescia - Italy

**Key References:**  
Hung RJ. et al. *Carcinogenesis*. 2004 Jun;25(6):973-8.  
Hung RJ. et al. *Int J Cancer*. 2004 Jul 1;110(4):598-604.  
Hung RJ. et al. *Cancer Epidemiol Biomarkers Prev*. 2004  
Jun;13(6):1013-21.

**Additional researchers:**  
Cecilia Arici, Marcello Campagna, Angela Carta,  
Donatella Placidi, Antonio Scotto di Carlo

**Study Design:** Hospital-based case  
control

**Matching factors:** Age, gender,  
and hospital of admission

**Country:** Italy

**ICD-0-3 morphology codes:**  
8010/2, 8050/3, 8070/3, 8120/2,  
8120/3, 8130/2, 8130/3, 8246/3,  
8560/3

**Follow up of cases?**  
Yes (from 2007)

**Expected time of follow-up?**  
64 -120 months

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1997-2000	1997-2000
<b>Source population</b>	Province of Brescia	Province of Brescia
<b>Response rate (enrolled/eligible)</b>	93%	97%
<b>Total number enrolled</b>	216	220
<b>Subjects with DNA</b>	200	214
<b>Ethnic origin</b>	100% Caucasian	100% Caucasian
<b>Age: mean (range)</b>	63 (22-80)	63 (22-79)
<b>Gender: % males</b>	100	100

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking (only for non smokers-ex smokers)	x	x
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts	x	x
Arsenic exposure	-	-
Other environmental exposures	x	x
Hair dye use (available after follow up)	x	-
Drug use (available after follow up)	x	-
Medical History (available after follow up)	x	-
Family History	-	-
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements	-	-
Other information, please specify (alcohol, tea, soft drinks; diuresis)	x	x

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	x	x
Cryopreserved whole blood / lymphocytes	x	x
Red blood cells	x	x
Urine samples	-	-
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	-	-

Frozen tissue -

**For Cases Only**

**Information at time of diagnosis**

Histological confirmation	X
Number of tumors (available after follow up)	X
Tumor site	X
Tumor size	-
Tumor grade	X
Growth pattern	X
Treatment of primary tumor	X
Stage	X
Other information, please specify	-

**Follow-up information**

Treatment information	X
Tumor recurrence	X
Tumor progression	X
Survival	X
Histological confirmation	X
Number of tumors	X
Tumor site	X
Tumor size	X
Tumor grade	X
Growth pattern	X
Stage	X
Active smoking	X
Occupational exposures	X
Drug use	X
Medical History	X
Quality of life	-
Caffeine intake	X
Fluid intake	X
Other information , please specify (as above)	X

**Study Name:**

The Belgian case control study on bladder cancer

**Institution:**Acad.Huisartsgeneeskunde, Catholic University of Leuven (KUL), Belgium  
Comprehensive Cancer Institute Limburg, Belgium**Principal Investigators:**Maurice Zeegers  
Frank Buntinx**Institution address:**Acad.Huisartsgeneeskunde, KUL  
Kapucijnenvoer 33 Blok J  
3000 Leuven  
Belgium  
Tel 32/(0)16 33 74 93**Key References:**Kellen E., et al. *Int J Cancer*. 2006 May 15;118(10):2572-8., Kellen E., et al.. *Int J Urol*. 2006 Sep;13(9):1180-4., Kellen E., et al.. *Cancer Lett*. 2007 Jan 8;245(1-2):51-60**Additional researchers:**

Eliane Kellen

**Study Design:** Population-based case control**Matching factors:** None**Country:** Belgium**ICD-0-3 morphology codes:** 81203**Follow up of cases?** No**Expected time of follow-up?** N.A.

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	2003-2005	2003-2005
<b>Source population</b>	Cancer registry	Population
<b>Response rate (enrolled/eligible)</b>	Not known	26%
<b>Total number enrolled</b>	200	386
<b>Subjects with DNA</b>	200	386
<b>Ethnic origin</b>	100% Caucasian	100% Caucasian
<b>Age: mean (range)</b>	67.67	64.24
<b>Gender: % males</b>	86	59

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc.)	x	x
Active smoking	x	x
Passive smoking	-	-
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts	-	-
Arsenic exposure	x	x
Other environmental exposures	x	x
Hair dye use	-	-
Drug use	-	-
Medical History	x	x
Family History	x	x
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements	-	-
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	x	x
Serum/plasma	x	-
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	-
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	-	-

**For Cases Only**

Information at time of diagnosis	
Histological confirmation	X
Number of tumors	-
Tumor site	X
Tumor size	-
Tumor grade	-
Growth pattern	-
Treatment of primary tumor	-
Stage	-
Other information, please specify	-
Follow-up information	
Treatment information	-
Tumor recurrence	-
Tumor progression	-
Survival	-
Histological confirmation	-
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	-
Growth pattern	-
Stage	-
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-

**Study Name:**  
French Bladder Cancer Study (FBCS)

**Institution:**  
INSERM U794 and CNRS FRE2939

Institut Gustave Roussy, Villejuif France

**Principal Investigators:**  
INSERM/CNRS: Simone Benhamou, Alain Sarasin

**Institution address:**  
INSERMU794/CNRS FRE2939  
Institut Gustave Roussy  
Espace Maurice Tubina (-1)  
94805 Villejuif, France

DBS: Agnès Laplanche

Department of Biostatistics and Epidemiology (DBS)  
Institut Gustave Roussy  
Rue Camille Desmoulins,  
94805 Villejuif cedex, France

**Key References:**  
Benhamou S. et al. Mutagenesis. 2003 Sep;18(5):445-8

**Additional researchers:**  
Stefan Michiels (DBS)  
Thomas Boulet (DBS)  
Philippe Dessen (CNRS)

**Study Design:** Hospital-based case control

**Matching factors:** Age, gender and hospital

**Country:** France

**ICD-0-3 morphology codes:** 81203

**Follow up of cases:** Yes  
(but not for all cases)

**Expected time of follow-up:** 60 months

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	1997-2001	1997-2001
<b>Source population</b>	3 general hospitals in Paris	3 general hospitals in Paris
<b>Response rate (enrolled/eligible)</b>	95%	95%
<b>Total number enrolled</b>	201	322
<b>Subjects with DNA</b>	195	320
<b>Ethnic origin</b>	100% Caucasian	100% Caucasian
<b>Age: mean (range)</b>	66 (30-89)	67 (34-92)
<b>Gender: % males</b>	84%	85%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	-	-
Occupational exposures	x	x
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	-	-
Hair dye use	-	-
Drug use	-	-
Medical History	-	-
Family History	-	-
Quality of life	-	-
Diet/nutrition	-	-
Caffeine intake	x	x
Fluid intake	-	-
Urine pH measurements	-	-
Other information, please specify	-	-

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	-	-
Cryopreserved whole blood / lymphocytes	-	-

Red blood cells	-	-
Urine samples	-	-
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	X	
Frozen tissue	-	

For Cases Only

#### Information at time of diagnosis

Histological confirmation	X
Number of tumors	X
Tumor site	-
Tumor size	X
Tumor grade	X
Growth pattern	-
Treatment of primary tumor	X
Stage	X
Other information, please specify	-

#### Follow-up information

Treatment information	X
Tumor recurrence	X
Tumor progression	X
Survival	X
Histological confirmation	X
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	X
Growth pattern	-
Stage	X
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-

**Study Name:**

The South and East China case control study on Bladder Cancer. SEarCh

**Institution:**Department of Public Health and Epidemiology  
University of Birmingham, UK**Principal Investigators:**

Maurice Zeegers

**Institution address:**Unit of Genetic Epidemiology  
Department of Public Health and Epidemiology  
University of Birmingham, Public Health Building  
Edgbaston, Birmingham, B15 2TT England**Key References:****Additional researchers:**

Marjolein Hemelt

**Study Design:**

Hospital-based case control

**Matching factors:**Frequency matched on age, sex,  
hospital**Country:**

China

**ICD-0-3 morphology codes:**

801203, 81303, 80703

**Follow up of cases?**

No

**Expected time of follow-up?**

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
<b>Years of enrollment</b>	2005-continuing	2005-continuing
<b>Source population</b>	4 hospitals in 4 cities in China	4 hospitals in 4 cities in China
<b>Response rate (enrolled/eligible)</b>	95%	95%
<b>Total number enrolled</b>	225/yr	225/yr
<b>Subjects with DNA</b>	95%	95%
<b>Ethnic origin</b>	Asian	Asian
<b>Age: mean (range)</b>	70, 30-93	70, 30-93
<b>Gender: % males</b>	80%	80%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	-	-
Hair dye use	x	x
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements	-	-
Other information, please specify: Hairdye, physical activity	-	-

Biological Samples	Cases	Controls
Blood DNA	-	-
Buccal DNA	x	x
Serum/plasma	-	-
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	-
Toenail clippings	x	x
Others, please specify	-	-
Paraffin tissue blocks	-	-
Frozen tissue	-	-

**For Cases Only**

Information at time of diagnosis	
Histological confirmation	X
Number of tumors	-
Tumor site	X
Tumor size	-
Tumor grade	X
Growth pattern	-
Treatment of primary tumor	-
Stage	X
Other information, please specify	-
Follow-up information	
Treatment information	-
Tumor recurrence	-
Tumor progression	-
Survival	-
Histological confirmation	-
Number of tumors	-
Tumor site	-
Tumor size	-
Tumor grade	-
Growth pattern	-
Stage	-
Active smoking	-
Occupational exposures	-
Drug use	-
Medical History	-
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-